<div><div></div><div>NeOnc Technologies executed a series of private placements between January and April 2026 to fund NEO216 preclinical trials, selling common stock at $7.20 per share with five-year warrants exercisable at $9.00. The company raised about $14.1 million across four Securities Purchase Agreements: $10.0 million in January, approximately $0.62 million in late February, $1.0 million in March, and about $2.0 million in April. Each agreement included customary terms, with offerings under the first two closing by month-end and the latter two scheduled to terminate on April 30, 2026.Agreement 1: NeOnc Technologies Raises $10.0 Million in Private Placement at $7.20; Five-Year $9.00 Warrants<ul><li>Agreement type: Securities Purchase Agreement for private placement of common stock and warrants</li><li>Counterparty: Single Institutional Investor</li><li>Signed / Effective: Jan 29 2026 / same</li><li>Duration / Termination: Warrants 5 years; offering through Jan 31 2026</li><li>Reason: Fund NEO216 preclinical trials</li></ul>Agreement 2: NeOnc Technologies Adds $0.62 Million Follow-On Private Placement; $7.20 Shares, $9.00 Warrants<ul><li>Agreement type: Securities Purchase Agreement for private placement of common stock and warrants</li><li>Counterparty: Three Investors</li><li>Signed / Effective: Feb 24 2026 / same</li><li>Duration / Termination: Warrants 5 years; offering through Feb 28 2026</li><li>Reason: Fund NEO216 preclinical trials</li></ul>Agreement 3: NeOnc Technologies Secures $1.0 Million in Third Private Placement; 138,889 Shares at $7.20<ul><li>Agreement type: Securities Purchase Agreement for private placement of common stock and warrants</li><li>Counterparty: One Investor</li><li>Signed / Effective: Mar 20 2026 / same</li><li>Duration / Termination: Warrants 5 years; offering through Apr 30 2026</li><li>Reason: Fund NEO216 preclinical trials</li></ul>Agreement 4: NeOnc Technologies Raises About $2.0 Million in Fourth Private Placement to Support NEO216<ul><li>Agreement type: Securities Purchase Agreement for private placement of common stock and warrants</li><li>Counterparty: One Investor</li><li>Signed / Effective: Apr 20 2026 / same</li><li>Duration / Termination: Warrants 5 years; offering through Apr 30 2026</li><li>Reason: Fund NEO216 preclinical trials</li></ul>Original SEC Filing: NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ] - 8-K - Apr. 24, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

NTHI

LABU

NeOnc Technologies raised approximately $14.1 million through four private placements from January to April 2026 to fund NEO216 preclinical trials. The company sold common stock at $7.20 per share, with five-year warrants exercisable at $9.00. The placements included $10 million in January, $0.62 million in February, $1 million in March, and $2 million in April, with customary terms for each Securities Purchase Agreement. The offerings are set to close by the end of their respective months, with the last two terminating on April 30, 2026.

TradingView

Neonc Tech

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VG Health

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

NeOnc Technologies Raises About $14.1 Million Across Four Private Placements to Fund NEO216